AARD NASDAQ
Aardvark Therapeutics, Inc. Common Stock
1W: -66.7%
1M: -75.3%
3M: -75.6%
YTD: -90.1%
1Y: -87.8%
$1.30
+0.22 (+20.37%)
Pre-Market: $1.27 (-0.03, -1.92%)
Weekly Expected Move ±33.3%
$0
$1
$1
$2
$2
Credit Risk of going bust: higher than 91% of companies Debt: 2.3% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the riskiest tenth, about 1 in 20 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.02 (down 99%), Aardvark Therapeutics, Inc. Common Stock would be worth roughly what it owes.
Total debt $677K against a stock market value of $28.5M.
Distance to default 1.51 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $539K (short-term plus half of long-term), stock volatility 173.6%; Altman Z'' 5.92. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.02 (down 99%), Aardvark Therapeutics, Inc. Common Stock would be worth roughly what it owes.
Total debt $677K against a stock market value of $28.5M.
Distance to default 1.51 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $539K (short-term plus half of long-term), stock volatility 173.6%; Altman Z'' 5.92. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (44)
All You Need to Know About Aardvark Therapeutics, Inc. (AARD) Rating Upgrade to Buy
Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aardvark Therapeutics, Inc. - AARD
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD
12 Health Care Stocks Moving In Friday's Intraday Session
This Unity Bancorp Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday
FDA Halts Aardvark Therapeutics Rare Disease Study
12 Health Care Stocks Moving In Friday's Pre-Market Session
Why Figma Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
12 Health Care Stocks Moving In Thursday's After-Market Session
Aardvark Therapeutics Plans to Unblind HERO and OLE Data to Inform Path Forward Following FDA Clinical Hold
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate– Hagens Berman
Aardvark Therapeutics GAAP EPS of -$0.99
Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate– Hagens Berman
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate– Hagens Berman
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD
Aardvark Therapeutics GAAP EPS of -$0.81 beats by $0.02
Aardvark Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Aardvark Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
12 Health Care Stocks Moving In Friday's Intraday Session
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD
Aardvark Therapeutics, Inc. Investigated by the Portnoy Law Firm
AARD Investors Have Opportunity to Join Aardvark Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
What's Going On With Aardvark Therapeutics Stock On Wednesday?
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD
This MongoDB Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Crude Oil Rises Sharply; Sealed Air Posts Upbeat Earnings
12 Health Care Stocks Moving In Monday's Intraday Session
Dow Falls 150 Points; ISM Manufacturing PMI Edges Lower In February
This Novo Nordisk Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
10 Health Care Stocks Moving In Monday's Pre-Market Session
Why Is Aardvark Therapeutics Stock Sinking Monday?
Stock Market Today: S&P 500, Dow Jones Futures Slide Amid War Against Iran— AMTD Digital, Aardvark, MongoDB In Focus
Why AMTD Digital Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket
Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aardvark Therapeutics Announces Establishment of New U.S. Subsidiary to Support Development of Its Dermatology Pipeline; Bryan Jones Named Chief Executive Officer
Aardvark Therapeutics Announces Leadership Appointments
Aardvark Therapeutics, Inc. (NASDAQ:AARD) Given Consensus Recommendation of “Moderate Buy” by Analysts
Aardvark's Hunger Suppressing Drug Candidate Could Potentially Address Massive $10 Billion Market: Analyst
Aardvark Therapeutics Announces First Patient Dosed in Australia in HERO Phase 3 Trial for Prader-Willi Syndrome
Analysts Set Aardvark Therapeutics, Inc. (NASDAQ:AARD) PT at $30.63
Aardvark Therapeutics to Present at Upcoming Investor Conferences in December